VIRIOS THERAPEUTICS INC (VIRI) Stock Overview
USA - NASDAQ:VIRI - US92829J1043 - Common Stock
VIRI Key Statistics, Chart & Performance
The current stock price of VIRI is 0.155 USD. In the past month the price decreased by -11.68%. In the past year, price decreased by -80.5%.
VIRI Latest News, Press Relases and Analysis
VIRI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.4 | 400.37B | ||
| AMGN | AMGEN INC | 13.39 | 157.27B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 145.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.62 | 106.92B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.51 | 69.24B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.37B | ||
| ARGX | ARGENX SE - ADR | 90.66 | 51.41B | ||
| INSM | INSMED INC | N/A | 35.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.76B | ||
| NTRA | NATERA INC | N/A | 26.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.22B | ||
| BIIB | BIOGEN INC | 9.27 | 21.75B |
Related stock screener links
About VIRI
Company Profile
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The company is headquartered in Alpharetta, Georgia. The company went IPO on 2020-12-17. The firm is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
Company Info
VIRIOS THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA US
Employees: 4
Phone: 18666208655
VIRIOS THERAPEUTICS INC / VIRI FAQ
What does VIRI do?
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The company is headquartered in Alpharetta, Georgia. The company went IPO on 2020-12-17. The firm is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
Can you provide the latest stock price for VIRIOS THERAPEUTICS INC?
The current stock price of VIRI is 0.155 USD. The price increased by 12.4% in the last trading session.
Does VIRI stock pay dividends?
VIRI does not pay a dividend.
What is the ChartMill rating of VIRIOS THERAPEUTICS INC stock?
VIRI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VIRIOS THERAPEUTICS INC?
VIRIOS THERAPEUTICS INC (VIRI) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of VIRI stock?
VIRIOS THERAPEUTICS INC (VIRI) has a market capitalization of 172.05K USD. This makes VIRI a Nano Cap stock.
VIRI Technical Analysis
VIRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VIRI. The financial health of VIRI is average, but there are quite some concerns on its profitability.
VIRI Financial Highlights
Over the last trailing twelve months VIRI reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 56.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -145.66% | ||
| ROE | -168.89% | ||
| Debt/Equity | 0 |
VIRI Forecast & Estimates
8 analysts have analysed VIRI and the average price target is 1.43 USD. This implies a price increase of 821.29% is expected in the next year compared to the current price of 0.155.